OptiBiotix Health plc Presentation of abstract at Probiotics for cholesterol reduction

OptiBiotix Health PLC
[shareaholic app="share_buttons" id_name="post_below_content"]

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today that it has had an abstract accepted for presentation at the International Scientific Conference on Probiotics and Prebiotics in Budapest, Hungary from 20 – 22 June 2017 (IPC2017). IPC2017 is the largest scientific conference worldwide focusing on probiotics and prebiotics for scientists, researchers, product developers, industry and the investment community. The conference attracts up to 500 leading scientists, opinion leaders, investors, and clinicians from more than 80 countries.

The abstract, titled “The Development of a Targeted Synergistic Synbiotic for Lactobacillus plantarum LPLDL®”, describes how by combining its OptiScreen® and OptiBiotic®, OptiBiotix were able to synthesise a dietary fibre that substantially enhances the cholesterol reducing activity of LPLDL® in gut models. This creates the potential for next generation LPLDL® products with cholesterol reduction levels potentially approaching those of statins.

Commenting, Stephen O’Hara, CEO of OptiBiotix Health plc said: “This abstract demonstrates the ability of OptiBiotix to create targeted prebiotics which when combined with a probiotic greatly enhances the probiotics growth and biological effect, in this case cholesterol reduction. This new research highlights the potential for the development of species or genera-specific probiotics to selectively enhance the growth and health benefits of existing probiotics. This has the potential to provide improved next generation products with enhanced performance and product differentiation in the probiotics functional food market, a market that is expected to be worth in excess of $46.5bn by 2020.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search